Resolvyx Pharmaceuticals Presentations at ARVO 2009

April 25, 2009

Resolvyx Pharmaceuticals, Inc., a resolvin therapeutics company, announced that new preclinical data on its resolvin drug candidates will be presented at ARVO.

As described in Resolvyx’s press release, resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, resolvins act to protect healthy tissue during an immuno-inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the insult has passed.

Resolvins are potential drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis. Such diseases include auto-immune diseases (like Crohn’s disease, psoriasis and rheumatoid arthritis), allergic diseases (like asthma) and chronic inflammatory diseases (like atherosclerosis, degenerative retinal diseases, chronic dry eye and Alzheimer’s disease).  In sum, resolvins offer a novel biological approach to treating significant inflammatory diseases, with a decreased potential for immuno-suppression.

Resolvyx will make presentations at five sessions at this year’s ARVO annual meeting, continuing the interest in resolving data from the eight presentations at last year’s 2008 ARVO meeting.

Resolvyx published the following titles and abstracts for each of its presentations:

Immunomodulation, Immunoregulation and Immunotherapies: RX-10001 (RvE1) an Endogenously Formed Immune Modulator Atenuates Clinical Signs of Autoimmune Disease in Rat CIA Model Concurrent with Inhibition of T-Cell Dependent Cytokines in Mixed Cell Populations from Draining Lymph Nodes

Angiogenesis: Topical Administration of RX-10045 Reduces Laser-induced Choroidal Neovascularization

Angiogenesis: An Analog of Resolvin E1 Inhibits Endothelial Cell Growth in Retina Following Laser-induced Choroidal Neovascularization

Stem Cells / Neuroprotection: Laser-Induced Choroidal Neovascularization Is Reduced by Neuroprotectin D1

Cell Signaling and Corneal Wound Healing: Cell Signaling Pathways Underlying Resolvin Induced Increases in Human Corneal Epithelial Cell Migration: Effects Of RX-10001 (RvE1) and RX-10008

Read the full release.

 

 



Comments

Jump down to form below to submit your own comments

Trackback URL
http://eyedocnews.com/00995-resolvyx-pharmaceuticals-presentations-at-2009-arvo/trackback/

Have insights to contribute? Please submit your comment below